NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional)
- Not stated
- Not stated
- Apr 26, 2024
Official announcement on nih_guide+grants_gov · opens the funder's page. Always confirm dates there.
Summary
The purpose of the NHLBI Emerging Investigator Award (EIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PDs/PIs) who are currently PDs/PIs on at least two NHLBI R01-equivalent awards (of which one must be an… […]
Other topics in this solicitation
Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed)
Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)
Catalyze Product Definition Medical Device prototype design/testing and disease target identification and assay development (R61/R33 - Clinical Trial Not Allowed)
Catalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)
Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
$350k
Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)
NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)
The rest of this announcement — free with an account
- The full announcement text, not the first two sentences
- All 6 review criteria reviewers score this against, extracted from this announcement
- Whether you are eligible — career stage, institution type, and the windows that close before the deadline does
- What similar funded projects received, from 219,000 past awards
More from National Institutes of Health
Computational Approaches to Curation at Scale for Biomedical Research Assets (R01 Clinical Trial Not Allowed)
$250k
HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
$350k